With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets ( [3]) , companies demonstrating disciplined pivotal execution and FDA ...

The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...

The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.

'Touch' encourages people to check for lumps on the neck, lips, or in their mouth. The 'open wide' part of the campaign aims ...

A new strategy that combines two types of PET scans can guide personalized radiotherapy for head and neck cancers, according ...

A recent retrospective study identifies key factors contributing to high failure rates of clinical trials evaluating treatments for head and neck squamous cell carcinoma.

Receiving a diagnosis of squamous cell carcinoma (SCC) can be an overwhelming experience, but it is important to remember ...

Researchers analyzed the health records of more than 33,800 U.S. veterans diagnosed with non-melanoma skin cancer and found ...

The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...

For the last 20 years, the standard-of-care adjuvant treatment for resected pathologically defined high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) has been ...

A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to ...

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...